Sign In
Buy MRKR
$1.45
+0.0300 (+2.11%)
At Close: Jun 03, 2026
Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
04:15pm, Wednesday, 15'th May 2024
Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study
Preliminary data from study in patients with lymphoma enrolled at City of Hope National Medical Center was presented at the 11 th Global Summit on Hematologic Malignancies in Whistler, BC, Canada
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
05:45pm, Monday, 25'th Mar 2024
Lead program in patients with lymphoma demonstrated preliminary safety and efficacy results with sustained complete response in first study participant treated with MT-601 (Neldaleucel) following CAR
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
12:30pm, Friday, 22'nd Mar 2024
HOUSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for t
HOUSTON, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for th
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
08:24am, Monday, 08'th Jan 2024
Strategic prioritization of clinical programs with focus on MT-601 in patients with lymphoma MultiTAA-specific T cell therapies demonstrate clinical safety and positive clinical data across multiple i
HOUSTON, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for t
Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
05:00pm, Thursday, 09'th Nov 2023
Announced complete response in first patient with lymphoma treated with MT-601 in Phase 1 APOLLO trial following CAR T relapse
Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse
07:00am, Monday, 11'th Sep 2023
Marker Therapeutics reports clinical updates in APOLLO trial for the treatment of lymphoma patients who have relapsed after anti-CD19 CAR T cell therapy
Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
08:00am, Wednesday, 30'th Aug 2023
HOUSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for th
Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies
09:03am, Thursday, 17'th Aug 2023
Cranford, New Jersey--(Newsfile Corp. - August 17, 2023) - Marker Therapeutics (NASDAQ: MRKR) highlights its technology during a recently held, 75-minute Demi-Colton Virtual Salon/Webinar on cell ther
Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
04:30pm, Monday, 14'th Aug 2023
Executed comprehensive non-dilutive agreement with Cell Ready TM , resulting in an extended financial runway into the fourth quarter of 2025
HOUSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for th
HOUSTON, July 10, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for th
Utilizing Fundamental Analysis for Your Penny Stocks? 3 Tips
06:00am, Thursday, 01'st Jun 2023
Penny stocks, often defined as shares trading for less than $5, present a unique opportunity for investors seeking high potential returns. Despite their low market price, these stocks can offer signif
